US FDA adds pharmacology to growing pile of draft biosimilar guidances
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has published another draft guidance on biosimilar product development, this time on clinical pharmacology studies1. The agency says the guidance will help companies design studies to show that there are no "clinically meaningful differences" between the biosimilar and its reference drug.